Daniel Falkenhain López-rekin lankidetzan egindako argitalpenak (8)

2023

  1. Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T363-T365

  2. Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 363-365

2022

  1. Eczematous reactions induced by anti-IL17 agents: Report of two cases and possible pathogenic mechanisms

    Indian Journal of Dermatology

  2. Ocular manifestations in psoriasis

    Piel, Vol. 37, Núm. 1, pp. 32-36

  3. SAPHO syndrome with severe acne in adolescent patients

    Piel, Vol. 37, Núm. 10, pp. 624-629

  4. Two clinical subtypes with different management of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: A single centre experience

    Dermatologic Therapy

2021

  1. Hydroxychloroquine-induced acute generalized exanthematous pustulosis: an adverse reaction to keep in mind during COVID-19 pandemic

    JDDG - Journal of the German Society of Dermatology

2020

  1. The broad spectrum of dermatological manifestations in COVID-19: clinical and histopathological features learned from a series of 34 cases

    Journal of the European Academy of Dermatology and Venereology